NAS
ARQT icon

Nykredit A/S’s Arcutis Biotherapeutics ARQT Stock Holding History

Nykredit A/S’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.3K Buy
+2,415
New +$56.3K ﹤0.01% 1441

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Nykredit A/S's ARQT Position: Q2 2026 in Review

Nykredit A/S opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 2,415 shares worth $63.3K. The stake represents ﹤0.01% of the portfolio and ranks #1441 among its holdings.

183 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Nykredit A/S held 2,415 shares of Arcutis Biotherapeutics worth $63.3K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Nykredit A/S position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1441 holding.
  • 183 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.